Rite Aid on Wednesday updated its guidance in response to a soft cough-cold and flu season, as well as ongoing COVID-19 impacts and challenging weather. For the company's fiscal 2021, ended Feb. 27, Camp Hill, Pa.-based Rite Aid said it expects a net loss of between $90 million and $100 million, with revenue expected to be roughly $24 billion and adjusted EBITDA pegged at roughly $425 million to $435 million. Additionally, the company noted that front-end comparable-store sales declined roughly 5.6% in the fourth quarter, driven by a nearly 37% decline in cough-cold and flu-related categories. "During the fourth quarter our industry was impacted by a historically soft cough, cold and flu season, as well as the continued impacts of COVID on the deferral of elective procedures and related acute prescription volume and selling, general and administrative expenses.